Last updated: July 29, 2026
Gralise is gabapentin enacarbil, an oral extended-release prodrug of gabapentin, marketed for postherpetic neuralgia. The current clinical-development and competitive outlook is shaped primarily by (1) loss of branded exclusivity risk for gabapentin enacarbil formulations and (2) the depth of patent coverage for dose forms, release characteristics, and manufacturing methods listed in FDA Orange Book records tied to Gralise.
What is the latest clinical trials update for Gralise (gabapentin enacarbil)?
Answer: Public registries show limited active, sponsor-led, late-stage trials for Gralise as a standalone branded product. Most observable development activity typically shifts to supplemental studies (bioequivalence, pharmacokinetics, adherence studies, or label expansion) rather than large confirmatory programs, given the product’s maturity and the prodrug-class competitive pressure.
Which trial types tend to remain for Gralise post-approval?
- Bioavailability and food-effect studies
- Pharmacokinetic comparability for line extensions and generic entrants
- Real-world or adherence-focused studies
- Safety/tolerability studies in specific populations
What endpoints dominate Gralise-style clinical programs?
- Pain intensity reduction scales used in neuropathic pain
- Sleep quality measures when included
- Responder analyses (proportion achieving predefined pain reduction thresholds)
- Treatment-emergent adverse events focused on somnolence, dizziness, and CNS effects
What is the practical implication for investors and BD teams?
When registrational-level activity is scarce, market outcomes are driven more by exclusivity and Orange Book barriers than by new clinical differentiation. That makes patent estate strength, Orange Book listing granularity, and any Hatch-Waxman Paragraph IV filings the highest-signal items for near-to-midterm trajectory.
How big is the Gralise market and what are current market drivers?
Answer: Gralise’s market is concentrated in US postherpetic neuralgia prescribing, with growth tied to neurologist and pain specialist adoption, payer formulary positioning, and competition from other gabapentinoids and neuropathic pain therapies.
Key demand drivers
- Neuropathic pain prevalence and guideline persistence for postherpetic neuralgia
- Tolerability profile relative to older neuropathic agents
- Once-daily/extended-release convenience (adherence lever vs immediate-release gabapentin)
Key supply-side and channel drivers
- Managed care restrictions and step edits
- Pharmacy benefit pricing pressure as generics approach
- Substitution behavior across the gabapentinoid class (plan-level switching)
Where competitive pressure comes from
- Immediate-release gabapentin (generic, often lower WAC)
- Pregabalin (branded legacy, then generics)
- Non-gabapentinoid options in neuropathic pain (SNRI and TCA classes), used depending on payer and tolerability
When does Gralise lose exclusivity in the US?
Answer: Gralise exclusivity and patent expiration timing is determined by the Orange Book publication and the controlling listed patents for the approved strength(s) and dosage form(s). For a branded gabapentinoid prodrug, the practical generic trigger is usually a Paragraph IV challenge to one or more listed patents, combined with approval of a chemically equivalent extended-release dosage form.
How exclusivity usually clears for extended-release oral prodrugs
- Composition of matter and formulation patents often expire before the last “process or use” barriers
- Method of manufacturing and control strategies for release profiles can extend market delay
- Device is not relevant here; the focus is oral extended-release formulation IP
What patents protect Gralise (gabapentin enacarbil) and which block generics?
Answer: The Gralise patent estate that matters for generic delay typically covers formulation and manufacturing for gabapentin enacarbil extended-release tablets, plus any method-of-use or handling/controls patents tied to the approved dosing and release profile.
Patent estate segmentation teams should map
1) Composition and prodrug-related patents
- Protect gabapentin enacarbil compound and prodrug chemistry
- These usually provide the earliest expiration signal but can be eclipsed by later formulation listings
2) Formulation patents
- Protect tablet composition and excipient system
- Protect release profile attributes (extended-release kinetics)
3) Manufacturing/process patents
- Protect granulation, coating, drying, and related process steps
- Protect stability and quality control strategies for the extended-release profile
4) Method-of-use patents
- Less common in older small-molecule analgesic brands but can exist if tied to dosing or clinical regimen
How to interpret Orange Book “blocking” vs “non-blocking” listings
Blocking depends on which listed patent(s) are:
- Applicable to the specific NDA strength/dosage form
- The basis for any FDA approval-designated patent list
- Asserted or challenged in litigation (Paragraph IV)
How strong is the patent estate for Gralise?
Answer: The strength is assessed by (1) number of listed patents by expiration date, (2) whether they cluster around formulation/manufacturing (harder for generics to design around), and (3) whether there has been sustained litigation activity or settlements that show enforceability.
What “strong” looks like for Gralise
- Multiple expiring patents in a tight window that cover different aspects of the dosage form
- Process/formulation claims with clear manufacturing control parameters
- Litigation history that yields court-adjudicated validity or sustained settlements
What “weaker” looks like
- Thin overlap across strengths/dosage forms
- Many patents with expiration dates earlier than major litigation events
- Settlement patterns that allow early entry of generic equivalents
What generic entry risks exist for Gralise?
Answer: Generic entry risk rises when (1) controlling formulation/process patents expire and (2) any Paragraph IV settlements enable “at-risk” or scheduled launch. The primary risk channel is the ability of generic manufacturers to meet release and bioavailability targets while navigating manufacturing IP.
Launch scenarios that matter
- Launch at first eligible date: after controlling patents expire or are cleared
- Launch after settlement: if a brand settlement triggers an agreed entry date
- At-risk launch: if court outcomes favor the generic challenger or if a settlement allows earlier launch
- Apples-to-oranges comparability: release profile differences can become a litigation topic if claims cover kinetics or in vitro profiles
What Paragraph IV challenges and patent litigation affect Gralise?
Answer: The most business-relevant inputs are whether there are active ANDA Paragraph IV certifications against listed Gralise patents, whether cases reached Markman rulings or summary judgment, and whether settlements specify entry dates.
Litigation signals to watch
- Claim construction outcomes tied to formulation/process limitations
- Court timelines that move launch eligibility
- Settlement terms that identify which patents were compromised and which were survived
What is the Orange Book status of Gralise (gabapentin enacarbil)?
Answer: Gralise’s Orange Book status is defined by the listed patents for each NDA strength and dosage form, each with an expiration date and regulatory exclusivity flags. The market impact is concentrated in patents with the latest expiration dates that remain “not expired” at the time of any ANDA approval.
How teams should use Orange Book data
- Build a strength-level expiration matrix (e.g., 300 mg, 600 mg, etc.)
- Identify the latest-expiring controlling patent(s)
- Track any patent term adjustments (PTA) that extend patent life
- Monitor patent maintenance and any late-listed patents that can shift generic timing
How does Gralise compare with gabapentin (immediate-release) and pregabalin in market access?
Answer: Gralise’s value proposition is adherence and dosing convenience from an extended-release prodrug. Immediate-release gabapentin and pregabalin are lower-cost generics, so payer access often depends on formulary placement, prior authorization criteria, and step therapy.
Commercial comparison factors
- Required daily dosing schedule
- GI/CNS adverse event profile differences that influence patient tolerance
- Plan tier placement and net price vs generic substitutes
- Clinical switching behavior after formulary changes
Which companies are competing with Gralise and what do their commercial strategies indicate?
Answer: Competition typically includes generic gabapentin enacarbil entrants if cleared by IP, plus established gabapentin and pregabalin brands and generics competing on formularies.
How to read competitor strategy
- If generics are late in launch, it signals patent barriers or tight release-profile litigation
- If payers drop Gralise to lower tiers early, it signals net price pressure and loss of formulary leverage
- If brand rebates increase, it signals active management of generic encroachment
What are Gralise formulation and manufacturing IP barriers for generic manufacturers?
Answer: For extended-release prodrugs, the manufacturing IP barrier usually centers on:
- How the tablet matrix is built (granulation/coating strategies)
- How release kinetics are tuned (in vitro dissolution characteristics)
- How stability and quality control are maintained during shelf life
Where design-around attempts usually focus
- Different excipient and coating systems that preserve release kinetics
- Different process parameters that avoid matching the patented method steps
- Different batch controls that meet FDA specs while distinguishing manufacturing IP
What FDA regulatory pathway issues matter for Gralise generics?
Answer: Generic approvals hinge on ANDA formulation comparability (bioequivalence and release profile conformity) and on IP carve-outs specified by FDA in the presence of Orange Book patents.
Regulatory risk points
- Bioequivalence failure due to release kinetics mismatch
- Patent-certification strategy that can trigger automatic statutory stays
- Potential need for multiple BE studies if strength-by-strength changes exist
What is the likely revenue and market projection for Gralise through exclusivity transitions?
Answer: In the absence of ongoing late-stage clinical differentiation, the projection is primarily an IP-and-formulary function:
- Revenue remains relatively stable while controlling Orange Book patents are in-force and before any scheduled generic launch date.
- Revenue compresses after the first generic entry with material formulary adoption and net price declines.
- Any delay due to litigation or settlements pushes the revenue step-down later rather than eliminating it.
Projection framework (business-ready)
- Base case: branded demand persists until controlling patent expiration; generic entry follows shortly after or after court/settlement triggers
- Downside case: earlier-than-expected entry due to favorable litigation or settlement terms
- Upside case: longer delay due to surviving “last-to-expire” formulation/process patents or extended PTA
- Monitoring items: Orange Book latest expiration date, court docket outcomes, settlement announced entry dates, payer formulary changes
Key Takeaways
- Gralise’s near-to-midterm trajectory is driven more by Orange Book patent timing and litigation than by new registrational clinical programs.
- Generic entry risk is concentrated in formulation and manufacturing method patents that can be harder to design around while matching extended-release performance.
- Market outcomes are tied to payer formulary placement and net price pressure after the first legally cleared generic launch date.
- The highest-signal watchlist items are: latest-expiring Gralise listed patents by strength, any ANDA Paragraph IV certifications, and settlement terms that specify entry timing.
FAQs
- What strengths of Gralise are most exposed to generic entry risk based on Orange Book listings?
- How do bioequivalence and extended-release dissolution targets affect Gralise generic approval likelihood?
- What role do patent term adjustments (PTA) and late-listed Orange Book patents play in delaying Gralise generics?
- How do Paragraph IV “not commercial manufacture/use” certifications change Gralise litigation and stay timelines?
- How does formulary step therapy for postherpetic neuralgia shift Gralise versus gabapentin/pregabalin prescribing after generic entry?
References (APA)
- US Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- ClinicalTrials.gov. (n.d.). Search results for “gabapentin enacarbil” and “Gralise.” National Library of Medicine.
